NASDAQ:STDY - SteadyMed Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.73
+0.30 (1.20%)
Get New SteadyMed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STDY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STDY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for SteadyMed in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.73.

This chart shows the closing price for STDY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in SteadyMed. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/1/2018JMP SecuritiesReiterated RatingMarket Outperform ➝ Market PerformMedium
1/10/2018JMP SecuritiesReiterated RatingBuyMedium
4/5/2017JMP SecuritiesReiterated RatingOutperform$11.00 ➝ $17.00Medium
4/3/2017HC WainwrightReiterated RatingBuy$10.00 ➝ $15.00High
11/7/2016HC WainwrightInitiated CoverageBuy$10.00N/A
(Data available from 6/21/2016 forward)

SteadyMed

SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical company that focuses on the development and commercialization of drug product candidates for the treatment of orphan and high-value diseases with unmet parenteral delivery needs. The company's product candidates are enabled by its proprietary PatchPump, a discreet, water-resistant, and disposable drug administration technology. Its lead drug product candidate is Trevyent that is used for treating pulmonary arterial hypertension. The company also develops two drug product candidates for the treatment of post-surgical and acute pain in the home setting. It has operations in Israel, the United States, and Europe. SteadyMed Ltd. was founded in 2005 and is headquartered in San Ramon, California.
Read More

Today's Range

Now: $4.73
Low: $4.73
High: $4.73

50 Day Range

MA: N/A

52 Week Range

Now: $4.73
Low: $2.60
High: $6.45

Volume

160 shs

Average Volume

85,138 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of SteadyMed?

The following Wall Street research analysts have issued stock ratings on SteadyMed in the last year:
View the latest analyst ratings for STDY.

What is the current price target for SteadyMed?

0 Wall Street analysts have set twelve-month price targets for SteadyMed in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for SteadyMed in the next year.
View the latest price targets for STDY.

What is the current consensus analyst rating for SteadyMed?

SteadyMed currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for STDY.

What other companies compete with SteadyMed?

How do I contact SteadyMed's investor relations team?

SteadyMed's physical mailing address is 5 OPPENHEIMER STREET, REHOVOT L3, 7670105. The company's listed phone number is 925-272-4999 and its investor relations email address is [email protected] The official website for SteadyMed is www.steadymed.com.